- NewAmsterdam Pharma Company N.V. and Menarini Group recently reported that the EMA’s CHMP issued a positive opinion recommending EU-wide marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe) to treat primary hypercholesterolemia, including HeFH and mixed dyslipidemia.
- This opinion, grounded in Phase 3 data showing robust LDL-C reductions with placebo-like tolerability, could be pivotal for NewAmsterdam’s royalty and milestone-based partnership economics with Menarini across Europe.
- Next, we’ll assess how this positive CHMP opinion for Ubeslo and Evlarco shapes NewAmsterdam Pharma’s investment narrative and risk profile.
Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
What Is NewAmsterdam Pharma's Investment Narrative?
To own NewAmsterdam today, you have to believe obicetrapib can translate from strong LDL‑C data into a meaningful, durable franchise across cardiovascular and potentially neurological indications, without the company losing control of its cash burn. The CHMP’s positive opinion on Ubeslo and Evlarco is a clear step forward here, because it validates the clinical program and brings NewAmsterdam closer to royalty and milestone economics in Europe, even though Menarini holds the commercial reins. In the near term, the key swing factor still looks like the PREVAIL outcomes trial, along with execution on remaining Phase 3 programs, rather than this opinion alone. At the same time, a still‑loss‑making P&L, high board and management pay, and senior departures keep execution risk front and center.
Despite retreating, NewAmsterdam Pharma's shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other Perspectives
Simply Wall St Community members offer 3 very different fair value views, from around US$50 per share to a very large figure above US$1,000, underscoring how far apart expectations sit on obicetrapib’s commercial potential. Set that against the recent CHMP opinion and still‑heavy losses, and it becomes clear why many market participants are weighing regulatory progress against execution and funding risk before deciding where they stand.
Explore 3 other fair value estimates on NewAmsterdam Pharma - why the stock might be worth just $50.24!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free NewAmsterdam Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.
No Opportunity In NewAmsterdam Pharma?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- Find 38 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com